However, the use of such a mutant IDH1 inhibitor (AGI-5198) decreased D-2-HG levels in a dose dependent manner in three chondrosarcoma cell lines with endogenous IDH1 mutations, whereas proliferation and migration were not affected [39]. The gene discussed is IDH1; the disease is chondrosarcoma.